Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib.
Jackson RA, Britton RG, Jayne S, Lehmann S, Cowley CM, Trethewey CS, Smith VM, Schmid R, Fegan C, Walter HS, Dyer MJS. Jackson RA, et al. Among authors: walter hs. Blood Adv. 2023 Jul 25;7(14):3378-3381. doi: 10.1182/bloodadvances.2022009366. Blood Adv. 2023. PMID: 37257190 Free PMC article. No abstract available.
A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.
Walter HS, Rule SA, Dyer MJ, Karlin L, Jones C, Cazin B, Quittet P, Shah N, Hutchinson CV, Honda H, Duffy K, Birkett J, Jamieson V, Courtenay-Luck N, Yoshizawa T, Sharpe J, Ohno T, Abe S, Nishimura A, Cartron G, Morschhauser F, Fegan C, Salles G. Walter HS, et al. Blood. 2016 Jan 28;127(4):411-9. doi: 10.1182/blood-2015-08-664086. Epub 2015 Nov 5. Blood. 2016. PMID: 26542378 Free PMC article. Clinical Trial.
New Agents to Treat Chronic Lymphocytic Leukemia.
Walter HS, Salles GA, Dyer MJ. Walter HS, et al. N Engl J Med. 2016 Jun 2;374(22):2185-6. doi: 10.1056/NEJMc1602674. N Engl J Med. 2016. PMID: 27248633 Free article. No abstract available.
Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.
Walter HS, Jayne S, Rule SA, Cartron G, Morschhauser F, Macip S, Karlin L, Jones C, Herbaux C, Quittet P, Shah N, Hutchinson CV, Fegan C, Yang Y, Mitra S, Salles G, Dyer MJS. Walter HS, et al. Blood. 2017 May 18;129(20):2808-2810. doi: 10.1182/blood-2017-02-765115. Epub 2017 Apr 4. Blood. 2017. PMID: 28377400 Free PMC article. Clinical Trial. No abstract available.
Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy.
Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, Hodson A, Coats J, Narat S, Morley N, Dyer MJS, Collins GP. Eyre TA, et al. Among authors: walter hs. Haematologica. 2019 Feb;104(2):e68-e71. doi: 10.3324/haematol.2018.198812. Epub 2018 Sep 6. Haematologica. 2019. PMID: 30190341 Free PMC article. No abstract available.
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
Flinn IW, Gribben JG, Dyer MJS, Wierda W, Maris MB, Furman RR, Hillmen P, Rogers KA, Iyer SP, Quillet-Mary A, Ysebaert L, Walter HS, Verdugo M, Klein C, Huang H, Jiang Y, Lozanski G, Pignataro DS, Humphrey K, Mobasher M, Kipps TJ. Flinn IW, et al. Among authors: walter hs. Blood. 2019 Jun 27;133(26):2765-2775. doi: 10.1182/blood-2019-01-896290. Epub 2019 Mar 12. Blood. 2019. PMID: 30862645 Free PMC article. Clinical Trial.
Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia.
Danilov AV, Herbaux C, Walter HS, Hillmen P, Rule SA, Kio EA, Karlin L, Dyer MJS, Mitra SS, Yi PC, Humeniuk R, Huang X, Zhou Z, Bhargava P, Jürgensmeier JM, Fegan CD. Danilov AV, et al. Among authors: walter hs. Clin Cancer Res. 2020 Jun 15;26(12):2810-2818. doi: 10.1158/1078-0432.CCR-19-3504. Epub 2020 Mar 10. Clin Cancer Res. 2020. PMID: 32156743 Clinical Trial.
38 results